Stock SOBI SWEDISH ORPHAN BIOVITRUM AB
Add to a list
To use this feature you must be a member
Log inSign up

Company Swedish Orphan Biovitrum AB

Equities

SOBI

SE0000872095

Pharmaceuticals

Market Closed - Nasdaq Stockholm
Other stock markets
 16:29:49 26/04/2024 BST 		5-day change 1st Jan Change
281 SEK +0.07% Intraday chart for Swedish Orphan Biovitrum AB +7.66% +5.24%
04-26 Sobi Wins EU Regulatory Panel's Positive Opinion for Hemophilia A Drug MT
04-26 Sobi Receives Positive CHMP Opinion Recommending Approval of efanesoctocog alfa for Once-Weekly Treatment of Haemophilia A CI

Business Summary

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.

Number of employees: 1,752

Sales per Business

SEK in Million2022Weight2023Weight Delta
Haematology
60.4 %
10,831 57.6 % 13,370 60.4 % +23.44%
Immunology
34.5 %
6,679 35.5 % 7,635 34.5 % +14.31%
Specialty Care
5.1 %
1,280 6.8 % 1,119 5.1 % -12.58%

Sales per region

SEK in Million2022Weight2023Weight Delta
United States
36.8 %
7,364 39.2 % 8,148 36.8 % +10.65%
Europe
35.5 %
3,585 19.1 % 7,851 35.5 % +119.00%
Global
12.3 %
1,427 7.6 % 2,718 12.3 % +90.47%
Rest of the World
12.0 %
2,438 13.0 % 2,653 12.0 % +8.82%
Sweden
3.0 %
667 3.5 % 660 3.0 % -1.05%
North America
0.4 %
77 0.4 % 93 0.4 % +20.78%

Managers

Managers TitleAgeSince
Guido Oelkers CEO
 Chief Executive Officer 59 21/05/17
Henrik Stenqvist DFI
 Director of Finance/CFO 57 19/07/18
Lydia Abad-Franch CTO
 Chief Tech/Sci/R&D Officer - -
Christine Wesström CTO
 Chief Tech/Sci/R&D Officer 49 31/12/09
Sven Ullman BRD
 Director/Board Member 68 31/12/20
Pablo de Mora SAM
 Sales & Marketing 56 31/12/18
Daniel Rankin PRN
 Corporate Officer/Principal 44 31/12/16
Mahmood Ladha PRN
 Corporate Officer/Principal 60 31/12/18
Norbert Oppitz PRN
 Corporate Officer/Principal 57 01/10/17
Armin Reininger PRN
 Corporate Officer/Principal 67 05/01/17

Members of the board

Members of the board TitleAgeSince
Sven Ullman BRD
 Director/Board Member 68 31/12/20
Annette Clancy CHM
 Chairman 70 07/05/14
Staffan Schüberg BRD
 Director/Board Member 55 31/12/19
Helena Ildiko Saxon BRD
 Director/Board Member 54 04/05/11
Filippa Stenberg BRD
 Director/Board Member - -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 1,621,178 0 1,621,178 ( 100.00 %) 50.87 %
Stock B 1 354,358,946 181,069,759 ( 51.10 %) 14,490,831 ( 4.089 %)

Shareholders

NameEquities%Valuation
Investor AB (Investment Company)
31.79 %
112,643,774 31.79 % 2 815 M kr
ASTRAZENECA PLC
9.059 %
32,100,518 9.059 % 802 M kr
Fjärde AP-fonden
5.941 %
21,051,463 5.941 % 526 M kr
SWEDISH ORPHAN BIOVITRUM AB
4.074 %
14,436,902 4.074 % 361 M kr
Swedbank Robur Fonder AB
3.251 %
11,519,623 3.251 % 288 M kr
Handelsbanken Fonder AB
1.789 %
6,338,022 1.789 % 158 M kr
Max Mitteregger Kapitalförvaltning AB
1.328 %
4,705,959 1.328 % 118 M kr
Livförsäkringsbolaget Skandia, ömsesidigt
1.257 %
4,453,769 1.257 % 111 M kr
Nordea Investment Management AB
0.9942 %
3,523,135 0.9942 % 88 M kr
Folksam
0.8702 %
3,083,727 0.8702 % 77 M kr

Holdings

NameEquities%Valuation
SWEDISH ORPHAN BIOVITRUM AB
4.07%
 14,436,902 4.07% 360,767,353 $

Company contact information

Swedish Orphan Biovitrum AB

Tomtebodavägen 23A

112 76, Solna

+46 86 97 20 00

http://www.sobi.com
address Swedish Orphan Biovitrum AB(SOBI)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per Business

Sales per region

Ratings for Swedish Orphan Biovitrum AB

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
281 SEK
Average target price
317.2 SEK
Spread / Average Target
+12.89%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.71B
CSL LIMITED Stock CSL Limited
-4.66% 86.13B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
UCB Stock UCB
+57.86% 25.23B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-16.09% 15.35B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-8.42% 8.12B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. SOBI Stock
  4. Company Swedish Orphan Biovitrum AB